Could an antidepressant slow COVID-19 progression?
RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...
Clinical Innovation Platform at the RI-MUHC announces first member company
Health tech accelerator welcomes AltPAP Innovation to its new state-of-the-art facility
The RI-MUHC leads new clinical trial of COVID-19 treatment for hospitalized patients
Phase 2 study tests LAU-7b, a Canadian drug with dual antiviral and inflammation-controlling effects
Dr. Ron Gottesman is Quebec’s Royal College Mentor of the Year
Mentorship applies to the whole team, whole person
New services for cancer patients at the RI-MUHC Centre for Innovative Medicine
The Centre for Innovative Medicine and Cedars Cancer Centre jointly offer additional space for infusion treatments
Project led by RI-MUHC researchers wins award at Oncopole's Priorité patient Competition
New grant supports integration of peer support and counselling ...
Understanding the psychological trauma related to facial transplantation
Dr. Mirko Gilardino is co-author of study that examines issues around patients’ consent
Supporting those grieving requires “literacy,” researcher Mary Ellen Macdonald suggests
Grief amidst the pandemic is an increasing reality in communities worldwide
Protecting lung cancer patients from COVID-19 – and learning from the experience
A study led by Dr. Nathaniel Bourganim tracked changes in treatment plans
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations